Etoposide + Granulocyte Colony-Stimulating Factor and Optional PLERIXAFOR (cas 110078-46-1) in Patients Who Failed Chemomobilization with or without PLERIXAFOR (cas 110078-46-1)

Add time:08/08/2019    Source:sciencedirect.com

We conducted a retrospective study of 62 patients undergoing etoposide (2 g/m2) + granulocyte colony-stimulating factor (G-CSF; 10 patients also received additional PLERIXAFOR (cas 110078-46-1)) as a salvage stem cell mobilization regimen after previous unsuccessful chemomobilization with or without plerixafor. The median peak CD34+ values after etoposide + G-CSF ± plerixafor was 54.07 CD34+/μL compared with 9.6 CD34+/μL after previous mobilization attempts (P < .001). The median yield was 6.33 × 106 CD34+ cells/kg per 2 apheresis. Etoposide + G-CSF ± plerixafor mobilization regimen resulted in 91.53% successful mobilizations and 89.83% of patients proceeding to autologous stem cell transplantation. All 7 patients who had previously failed plerixafor-based mobilization attempts were successfully mobilized with etoposide + G-CSF ± plerixafor and proceeded to autologous stem cell transplantation. The most common grades 3 to 4 adverse events of etoposide + G-CSF ± plerixafor were febrile neutropenia (69.35%), mucositis (51.62%), and bacteremia (20.97%). No fatal outcomes were observed. Rates of 12-month overall survival and progression-free survival were 88.71% and 70.97%, respectively. Etoposide + G-CSF ± plerixafor is an effective regimen for salvage stem cell mobilization also in patients who failed plerixafor, with most patients undergoing autologous stem cell transplantation. The adverse event rate may warrant a decrease in the dose of etoposide.

We also recommend Trading Suppliers and Manufacturers of PLERIXAFOR (cas 110078-46-1). Pls Click Website Link as below: cas 110078-46-1 suppliers

Prev:Efficient removal of dyes from aqueous solutions using a novel hemoglobin/iron oxide composite
Next:Mobilization of Leukemic Cells Using PLERIXAFOR (cas 110078-46-1) as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability)